Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Completed · Not applicable

Conditions studied: Non-Small Cell Lung Cancer

In brief

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

Key facts

Study ID

NCT00283478

Run by

Kentuckiana Cancer Institute

People needed

20

Starts

2004-05-01

Expected to finish

2007-04-01

Last updated by the study team

2007-10-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo
• Karnofsky score 60% or greater
• patients who will be treated with Gemcitabine

Where it is running

• Kentuckiana Cancer Institute — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.